Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Increases By 11.8%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 50,200 shares, a growth of 11.8% from the October 15th total of 44,900 shares. Based on an average trading volume of 35,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Maxim Group started coverage on Context Therapeutics in a research report on Monday, September 11th. They issued a “buy” rating and a $4.00 target price for the company. HC Wainwright upgraded shares of Context Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Wednesday, November 1st.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently made changes to their positions in the stock. State Street Corp bought a new position in shares of Context Therapeutics during the second quarter worth about $39,000. Northern Trust Corp acquired a new position in shares of Context Therapeutics in the 2nd quarter worth approximately $49,000. Atria Wealth Solutions Inc. bought a new stake in shares of Context Therapeutics in the 2nd quarter valued at $51,000. Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 47.4% during the second quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after buying an additional 9,100 shares during the period. Finally, Clear Harbor Asset Management LLC bought a new position in Context Therapeutics during the second quarter worth $58,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock traded down $0.01 during trading on Friday, hitting $1.00. The company’s stock had a trading volume of 12,922 shares, compared to its average volume of 623,241. The stock has a market cap of $15.97 million, a price-to-earnings ratio of -0.78 and a beta of 2.51. Context Therapeutics has a 52 week low of $0.47 and a 52 week high of $1.69. The stock has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $1.09.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.